Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma

Yuxuan Che, Ruolan Zeng, Dabei Tang, Ou Bai, Youchao Jia, Yuhuan Gao, Xiaojing Yan, Xiaolei Ding, Xiuli Sun, Xiaobo Wang, Bing Xu, Hui-Han Wang, Dongxia Qu, Liye Xu, Na Li, Qingyuan Zhang, Hui Zhou, Xiuhua Sun

Blood (2025) 146 (Supplement 1): 7142.

https://doi.org/10.1182/blood-2025-7142

Published: 2025

Journal Articles

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Blood (2025) 146 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2025-1843

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Blood (2025) 146 (Supplement 1): 776.

https://doi.org/10.1182/blood-2025-776

Published: 2025

Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Zhao Peiqi, Shu Zhao, Chen Huang, Jiesong Wang, Junqing Xu, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Ying Chen, Yanan Jiang, Yanbin Zheng, Daoguang Chen, Yuhuan Gao, Qingyuan Zhang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2024-205438

Published: 2024

Journal Articles

Multicellular Dynamics at Spatial Single-Cell Resolution Reveal Early Relapse of Hepatitis B Virus-Associated Follicular Lymphoma

Yuwei Deng, Qingyuan Zhang, Huilai Zhang, Jianli Ma

Blood (2024) 144 (Supplement 1): 6179.

https://doi.org/10.1182/blood-2024-193008

Published: 2024

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis

Fenghua Gao, Jing Liu, Jiesong Wang, Lihong Liu, Zhiming Li, Yuqin Song, Xudong Zhang, Hui Zhou, Xiuhua Sun, Wei Zhang, Bing Xu, Liping Su, Wen Shujuan, Rong Tao, Ou Bai, Qingyuan Zhang, Liqun Zou, Xianhuo Wang, Huilai Zhang

Blood (2023) 142 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2023-174308

Published: 2023

Journal Articles

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Yuqin Song, Shuhua Yi, Haiyan Yang, Ru Feng, Huiqiang Huang, Qingyuan Zhang, Yanyan Liu, Ye Guo, Huilai Zhang, Liling Zhang, Yijiao Qian, JianKun Zhu, Jun Zhu

Blood (2023) 142 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2023-173287

Published: 2023

Journal Articles

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Blood (2021) 138 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2021-149861

Published: 2021

Journal Articles

A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China

Zhong Zheng, Huilai Zhang, Jingwen Wang, Keshu Zhou, Li Zhang, Hui Zhou, Qingyuan Zhang, Weili Zhao

Blood (2021) 138 (Supplement 1): 3536.

https://doi.org/10.1182/blood-2021-150002

Published: 2021

Journal Articles

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141752

Published: 2020

Journal Articles

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Blood (2019) 134 (Supplement_1): 2878.

https://doi.org/10.1182/blood-2019-130603

Published: 2019

Journal Articles

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Blood (2019) 134 (Supplement_1): 2838.

https://doi.org/10.1182/blood-2019-126481

Published: 2019

Journal Articles

Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1

Jun Zhu, MD PhD, Grzegorz Nowakowski, MD, Qingyuan Zhang, Joshua Brody, MD, Xiuhua Sun, MD, Joseph Maly, MD, Yuqin Song, MD PhD, Yongping Song, MD PhD, Jennifer Kimberly Lue, MD, Wen Luo, PhD, Lei Zhang, MD, Isabel Han, Manoj Jivani, Young Liu, Ling Li, MD, Joan Sun, MBA, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 5330.

https://doi.org/10.1182/blood-2019-124930

Published: 2019

Journal Articles

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klanova, Laurie H. Sehn, Isabelle Bence-Bruckler, Federica Cavallo, Jie Jin, Maurizio Martelli, Douglas Stewart, Umberto Vitolo, Francesco Zaja, Qingyuan Zhang, Federico Mattiello, Gila Sellam, Elizabeth A. Punnoose, Edith Szafer-Glusman, Christopher R. Bolen, Mikkel Z. Oestergaard, Guenter R. Fingerle-Rowson, Tina Nielsen, Marek Trneny

Blood (2019) 133 (9): 919–926.

https://doi.org/10.1182/blood-2018-07-862862

Published: 2019

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Multicellular Dynamics at Spatial Single-Cell Resolution Reveal Early Relapse of Hepatitis B Virus-Associated Follicular Lymphoma

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only